Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2009
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • No disease focus
  • Location: Europe

Abstract

The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) is an effort of the European Commission’s Innovative Medicines Initiative that aims to advance methods for pharmacoepidemiology and pharmacovigilence, in partnership with the European Medicines Agency (EMA). The focus is to understand discrepancies between reported outcomes from pharmacoepidemiology studies by studying combinations of drugs and adverse events in several databases, to identify and explore sources of variability that may currently affect drug safety studies.

Mission

The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. In order to achieve this overall goal, PROTECT has been designed to develop and validate a set of innovative tools and methods that:

Consortium History

2009 – Project start date (January)
2013 – PROTECT project releases major pharmacovigilance databases (February)
2013 – The PROTECT team launches four-country survey on drug use by pregnant women
2013 – PROTECT releases reviews of benefit-risk methods and their visualization (July)
2014 – IMI published an updated version of the Drug Consumption Databases (February)

Structure & Governance

The PROTECT governance structure is a multi-layer structure comprising three components:

Governance and scientific oversight

Name

Affiliation

Expertise

Helen Dolk, PhD

Professor of Epidemiology at the University of Ulster, UK

Perinatal epidemiology,

pharmacoepidemiology

Trevor Gibbs, MD

Former Head of Global Pharmacovigilance and Product Safety, GSK, UK; Chief Medical Officer at ii4sm

Pharmacovigilance, health outcomes, public health

David Haerry

European AIDS Treatment Group, Brussels, Belgium

Pharmacoepidemiology

Vicky Hogan, PhD

Director, Office of Risk Management and Science, Marketed Health Products Directorate, Health Canada

Benefit-risk assessment

Michael Lewis, MD

EPES Epidemiology, Pharmacoepidemiology and Systems Research GmbH, Berlin, Germany

Pharmacoepidemiology

Allen Mitchell, MD

Slone Epidemiology Center, Boston, USA

Perinatal epidemiology, pharmacoepidemiology

Marcus Müllner, MD

Head of AGES PharmMed (Austrian Medicines and Medical Devices Agency), Austria

Benefit-risk assessment, clinical epidemiology, pharmacovigilance

Gerald Dal Pan, M.D., M.H.S.

Director, Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, USA

Pharmacovigilance, drug development, public health, and risk management

Munir Pirmohamed, M.D.

Department of Pharmacology and Therapeutics, University of Liverpool, UK

Pharmacology, pharmacovigilance

Samy Suissa, PhD

Department of Epidemiology/Biostatistics, McGill University, Montreal, Canada

Pharmacoepidemiology, Biostatistics

 

The Steering Committee has the central role in the governance structure and the management of the project. The Steering Committee includes all Work Package co-Leaders, the coordinator, the deputy coordinator, and their alternates.

During the initiation phase of the project, the Steering Committee will in principle meet every month. In the following years, the Steering Committee will meet at least four times annually.

Main roles and responsibilities:

  • Finalization and approval of the PROTECT Management Plan,

  • Decisions for the initiation and execution of the activities included in the Project Management Plan,

  • Approval of the budget allocation to Work Package members and the in-kind contribution from private partners,

  • Review of the progress and of the quality control findings of the work program,

  • Discussion of recommendations proposed by the External Advisory Board and the Consortium Assembly,

  • Decisions regarding communication and dissemination of the project deliverables,

  • Discussion of problems and conflicts that may arise during the course of the program when these have not been solved by the coordinator and the deputy coordinator, and

  • Decisions regarding the admission of new partners from the Extended Audience.

The coordinator is responsible for the successful management and delivery of the project. He is the contact point for discussions with the IMI JU and is in charge of the execution of the work plan with the Work Package co-leaders and of the implementation of the decisions taken by the Steering Committee. The coordinator is responsible for the overall governance of PROTECT.

The deputy coordinator has three main roles: to coordinate the input (scientific and in-kind) from the private consortium (i.e., industry partners) , to support the coordinator with the development and implementation of the Project Management Plan and delivery of outcomes, and to support the coordinator with governance of PROTECT and be involved in decision-making for the project.

Work Package

Co-Leaders

Partner

WP1

Xavier Kurz

EMA

 

Elizabeth Swain

GSK

WP2

Olaf Klungel

UU

 

Robert Reynolds

Pfizer

WP3

Niklas Norén

UMC

 

Michael Kayser

Bayer

WP4

Omer de Mol

Genzyme

WP5

Deborah Ashby

Imperial

 

Alain Micaleff

ME

WP6

Lucien Abenhaim

PGRx(LASER)

 

Laurent Auclert

SARD

WP7

Joan-Ramon Laporte

FICF

 

Elena Rivero

Novartis Pharma

Members of the Extended Audience are European centers that have established or have access to specific clinical trial data, patient registries, cohorts, or case-control resources, or individuals with expertise in specific domains to be addressed by WP6 (pharmacology, clinical expertise, pharmacoepidemiology).

Financing

This project is funded by the Innovative Medicines Initiative, a public-private partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), resources of which are composed of financial contributions from the EU Seventh Framework Programme and EFPIA companies’ in-kind contributions. Large pharmaceutical companies participating in IMI projects do not receive IMI funding.

The IMI Intellectual Property (IP) Policy governs the IP regime of all projects funded by the IMI JU.  To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk that can be contacted by e-mailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at the following address: http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

According to IMI’s intellectual property policy, the participants undertake to disseminate the data
as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The Project Agreement shall include a description of the material that must be disseminated in accordance with the IP Policy and referenced in the Grant Agreement. If the participants do not disseminate within such time periods without good reason, the Executive Office has the right to disseminate such results in a manner consistent with the Grant Agreement.

Points of Contact

Xavier Kurz
European Medicines Agency
Pharmacovigilance and Risk Management
London
United Kingdom

Elizabeth Swain
GlaxoSmithKline Research and Development
LTD,
Harlow
United Kingdom
 
Per Helboe
Danish Medicines Agency, Licensing Division
Copenhagen
Denmark

Sponsors & Partners

GlaxoSmithKline Research and Development LTD, Brentford, UK

Amgen NV, Brussels, Belgium

Bayer Schering Pharma AG, Berlin, Germany

AstraZeneca AB, Södertälje, Sweden

Genzyme Europe B.V., Naarden, The Netherlands

H. Lundbeck A/S, Valby, Denmark

Merck KGaA, Darmstadt, Germany

Novartis Pharma AG, Basel, Switzerland

Novo Nordisk A/S, Bagsvaerd, Denmark

Pfizer Limited, Sandwich, United Kingdom

F. Hoffmann-La Roche AG, Basel, Switzerland

Sanofi-Aventis Research and Development, Chilly-Mazarin, France

European Medicines Agency

Lægemiddelstyrelsen (Danish Medicines Agency) Copenhagen, Denmark

Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain

Fundación Centro Español de Investigación

Farmacoepidemiológica, Madrid, Spain

Fundació Institut Català de Farmacologia, Barcelona, Spain

International Alliance of Patients’ Organizations, London, UK

Imperial College of Science, Technology & Medicine, London, UK

Institut National de la Santé et de la Recherche Médicale, Paris, France

Ludwig-Maximilians-Universität München, München, Germany

Mario Negri Institute for Pharmacological Research, Milan, Italy

Medicines and Healthcare Products Regulatory Agency, London, UK

Rijksuniversiteit Groningen, Groningen, The Netherlands

Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden

University of Newcastle upon Tyne, Newcastle upon Tyne, UK

Universiteit Utrecht, Utrecht, The Netherlands

LA Santé Épidémiologie Evaluation Recherche, Paris, France

Outcome Europe Sarl, St. Prex, Switzerland


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.